Governance Jazz Pharmaceuticals plc

JAZZ

IE00B4Q5ZN47

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2025-12-15 pm EST			5-day change	1st Jan Change
169.53 ^USD	+1.21%		+0.35%	+37.66%

Dec. 11	Jazz Pharmaceuticals Insider Sold Shares Worth $379,366, According to a Recent SEC Filing	MT
Dec. 10	This Is Decision Day

Executive Committee: Jazz Pharmaceuticals plc

Manager

Positions heldSince

Renée Galá

53 year

Chief Executive Officer	2025-08-10
President	2023-09-30

Jeff Macdonald

Investor Relations Contact

Philip Johnson

60 year

Director of Finance/CFO

2024-02-29

Liz Henderson

53 year

Chief Tech/Sci/R&D Officer

2023-07-31

Neena Patil

50 year

General Counsel

2019-06-30

Robert Iannone

58 year

Chief Tech/Sci/R&D Officer

2019-05-28

Heidi Manna

54 year

Human Resources Officer

2018-10-31

Aislinn Doody

Corporate Secretary

Patricia Carr

54 year

Comptroller/Controller/Auditor

2019-07-31

Composition of the Board of Directors: Jazz Pharmaceuticals plc

Director

CommitteesSince

Bruce Cozadd

61 year

Chairman

2019-10-24

Norbert Riedel

67 year

Governance Committee	2013-05-12
Nominating Committee	2013-05-12
Audit Committee	2018-10-31
Compensation Committee	2018-10-31
Governance Committee Chair	2018-10-31
Nominating Committee Chair	2018-10-31
Compensation Committee Chair	2012-12-31

Heather McSharry

63 year

Audit Committee	2013-04-30
Governance Committee Chair	2013-04-30
Nominating Committee Chair	2013-04-30
Nominating Committee	2020-12-30
Compensation Committee Chair	2022-06-15

Mark Smith

73 year

Governance Committee Chair	2018-10-25
Nominating Committee Chair	2018-10-25
Executive Committee
Governance Committee
Nominating Committee

Ted Love

66 year

Governance Committee Chair
Nominating Committee Chair
Compensation Committee Chair	2023-08-02
Audit Committee	2025-11-30

Jennifer Cook

59 year

Governance Committee Chair	2018-11-05
Nominating Committee Chair	2018-11-05
Compensation Committee	2019-12-11
Compensation Committee Chair	2022-03-31

Patrick Enright

63 year

Compensation Committee Chair	2020-10-31
Audit Committee	2024-01-31
Compensation Committee	2022-10-31

Rick Winningham

65 year

Governance Committee	2014-06-23
Nominating Committee	2014-06-23

Anne O’Riordan

57 year

Audit Committee	2019-02-13
Compensation Committee	2019-02-13

Laura Hamill

60 year

Governance Committee Chair	2022-03-16
Compensation Committee	2024-07-24

Patrick Kennedy

56 year

Audit Committee Chair

2024-02-29

Seamus Mulligan

64 year

Director/Board Member	2012-01-17
Independent Dir/Board Member	2012-01-17

Latest Appointments: Jazz Pharmaceuticals plc

Nov. 12	Immix Biopharma, Inc. Appoints Michael Grabow as Chief Commercial Officer	CI
Oct. 28	Jazz Pharmaceuticals plc Announces Board Changes, Effective December 1, 2025	CI
Oct. 09	Ionis, Jazz Named Top Picks as US Biopharma Heads Into Steady Q3, BofA Says	MT
Oct. 01	Crane NXT, Co. Announces Appointment of Kim Dimaurizio as Senior Vice President and Chief People Officer, Effective October 1, 2025	CI
Aug. 05	Jazz Pharmaceuticals Renee Gala named as president and CEO effective August 11 - SEC filing	RE
Jul. 29	Compass Pathways plc Announces Board Changes	CI
Jul. 28	Lantern Pharma Inc. Announces Appointment of Lee Schalop to Board of Directors	CI

More news

Former Officers and Directors: Jazz Pharmaceuticals plc

Insider

Positions held

SinceUntil

Ken O'Keefe

Director/Board Member	2003-12-31	2025-11-30
Independent Dir/Board Member	2003-12-31	2025-11-30

Andrea N. Flynn

Investor Relations Contact

2024-11-30

Peter Gray

Director/Board Member	2013-05-07	2024-07-24
Independent Dir/Board Member	2013-05-07	2024-07-24

Catherine Sohn

Director/Board Member	2012-07-26	2024-07-24
Independent Dir/Board Member	2012-07-26	2024-07-24

Kim Sablich

Corporate Officer/Principal

2020-05-31

2023-12-30

Daniel Swisher

Chief Operating Officer	2018-01-02	2021-05-04
President	2018-01-02	2023-09-30

Finbar Larkin

Chief Tech/Sci/R&D Officer

2019-09-30

2023-07-31

Christopher Tovey

Chief Operating Officer

2021-05-04

2022-09-30

Anne Borgman

Corporate Officer/Principal

2018-12-31

2022-02-28

Elmar Schnee

Director/Board Member	2014-07-31	2021-07-28
Independent Dir/Board Member	2014-07-31	2021-07-28

Paul Berns

Director/Board Member	2012-01-17	2021-07-28
Independent Dir/Board Member	2012-01-17	2021-07-28

Lawrence Carter

Corporate Officer/Principal

2015-04-30

2020-12-31

Jacqueline Pomfret Kirby

Public Communications Contact	2016-12-31	2020-12-31
General Counsel	2016-12-31	2020-12-31

George Eliades

Corporate Officer/Principal

2020-11-30

Charles Williams

Corporate Officer/Principal

2012-12-31

2020-10-31

Michael Miller

Corporate Officer/Principal

2014-03-31

2020-08-31

Karen Wilson

Comptroller/Controller/Auditor	2011-01-31	2019-07-31
Director of Finance/CFO	2011-01-31	2020-08-31

Julie Patel

Corporate Officer/Principal

2016-01-31

2020-03-31

Matthew Young

Director of Finance/CFO	2014-03-09	2019-10-24
Private Equity Investor	2013-03-31	2019-10-24
Corporate Officer/Principal	2013-03-31	2014-03-09

Paul Treacy

Chief Tech/Sci/R&D Officer

2014-06-30

2019-09-30

Suzanne Hooper

General Counsel

2012-02-29

2019-02-28

Iain Robert McGill

Corporate Officer/Principal

2012-05-31

2018-12-31

Heather McGaughey

Human Resources Officer

2007-12-31

2018-06-30

Karen Smith

Chief Tech/Sci/R&D Officer

2015-03-31

2018-05-30

Craig Parker

Corporate Officer/Principal

2014-07-31

2018-02-28

Russell Cox

Chief Operating Officer	2014-05-18	2018-01-02
Corporate Officer/Principal	2012-01-17	2014-05-18

Kishor Soparkar

Corporate Officer/Principal

2006-10-31

2016-06-30

Larissa Schwartz

Corporate Officer/Principal

2012-09-30

2015-10-31

Jeffrey K. Tobias

Chief Tech/Sci/R&D Officer

2012-01-17

2015-03-31

Michael DesJardin

Corporate Officer/Principal

2004-06-30

2015-02-28

Sriram Ryali

Corporate Officer/Principal

2014-12-31

Fintan Keegan

Corporate Officer/Principal	2012-01-17	2012-08-23
Corporate Secretary	2012-01-17	2014-08-10

Kathryn Falberg

Director of Finance/CFO

2009-11-30

2014-03-08

James Momtazee

Director/Board Member

2004-01-31

2013-12-31

Bijan Nejadnik

Director/Board Member

2013-03-31

Diane H. Schrick

Public Communications Contact

2013-02-28

Katherine A. Littrell

Investor Relations Contact

2012-12-31

David Brabazon

Corporate Secretary

2012-01-17

Alan Sebulsky

Director/Board Member	2012-01-17	2012-06-30
Independent Dir/Board Member	2012-01-17	2012-06-30

Bryan Geoffrey Morton

Corporate Officer/Principal

2012-05-31

Carol Gamble

General Counsel	2012-01-17	2012-03-11
Corporate Secretary	2012-01-17	2012-03-11

Bryan Cressey

Director/Board Member	2012-01-17	-
Independent Dir/Board Member	2012-01-17	-

Mark G. Eller

Corporate Officer/Principal

2012-01-17

Michael Kelly

Sales & Marketing

2012-01-17

Eunan Maguire

Corporate Officer/Principal

2012-01-17

Janne L. T. Wissel

General Counsel

2012-01-17

Robert McKague

Compliance Officer

2012-01-17

Ami Knoefler

Public Communications Contact

2012-01-17

Robert M. Myers

Director/Board Member	2009-04-02	-
President	2009-04-02	-

Kevin Hickey

Sales & Marketing

Allen Yang

Corporate Officer/Principal	-	2018-12-31
Sales & Marketing	2018-12-31	-

Laurie Hurley

Corporate Officer/Principal

Jed Black

Corporate Officer/Principal

Age distribution of managers

Parity Men Women

Male	15
Female	11

Of which Executive Committee

Male	4
Female	5

Of which Directors

Male	8
Female	4

Revisions

Révisions CA 1 an

Révisions CA 4 mois

Révisions CA 1 mois

Révisions BNA 1 an

Révisions BNA 4 mois

ESG MSCI

Environnement

Social

Gouvernance

Polémique

Controverses Ethiques

Controverses sur les droits de l'Homme

Controverses Subventions fiscales

Conforme à la finance Islamique

Jazz Pharmaceuticals PLC is a biotechnology company. The Company is engaged in developing medicines for people with serious diseases. The Companyâs lead marketed products include Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, Xyrem (sodium oxybate) oral solution, Epidiolex (cannabidiol) oral solution, Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn), Zepzelca (lurbinectedin), Defitelio (defibrotide sodium) AND Vyxeos (daunorubicin and cytarabine) liposome for injection. The Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution product is for the treatment of cataplexy or excessive daytime sleepiness (EDS), in patients with narcolepsy seven years of age and older. The Xyrem (sodium oxybate) oral solution product is for the treatment of cataplexy or EDS in patients with narcolepsy seven years of age and older. The Defitelio (defibrotide sodium) product is for the treatment of hepatic veno-occlusive disease (VOD).

Employees

2,800

Sector

Pharmaceuticals

Calendar

Jan. 08 - American Society of Clinical Oncology Gastrointestinal Cancers Symposium - Abstract # LBA285

More about the company